BridgeBio Pharma, Inc. (BBIO), Monday announced the sale of a certain portion of royalties from sales of BEYONTTRA in Europe to HealthCare Royalty funds managed by Blue Owl Capital for $300 million.
BEYONTTRA is an orally administered near-complete stabilizer of transthyretin indicated for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy.
The transaction involves the sale of 60 percent of royalties on the first $500 million of annual BEYONTTRA net sales in Europe with an initial cap of 1.45x.
Last year, the company entered into an exclusive licensing agreement with Bayer Consumer Care AG to commercialize BEYONTTRA in Europe, receiving an upfront payment of $210 million and expecting to receive $75 million in near-term milestone payments.
In the pre-market hours, BBIO is trading at $44.40, down 1.03 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.